Circulating miRNA-23b and miRNA-143 are potential biomarkers for In-Stent Restenosis
Author
dc.contributor.author
Saavedra, Nicolás
Author
dc.contributor.author
Rojas, Gabriel
Author
dc.contributor.author
Herrera, Jesús
Author
dc.contributor.author
Rebolledo, Camilo
Author
dc.contributor.author
Ruedlinger, Jenny
Author
dc.contributor.author
Bustos, Luis
Author
dc.contributor.author
Bobadilla, Braulio
Author
dc.contributor.author
Pérez, Luis
Author
dc.contributor.author
Saavedra, Kathleen
Author
dc.contributor.author
Zambrano Coloma, Tomás
Author
dc.contributor.author
Lanas, Fernando
Author
dc.contributor.author
Salazar, Luis A.
Admission date
dc.date.accessioned
2021-01-28T18:15:09Z
Available date
dc.date.available
2021-01-28T18:15:09Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
BioMed Research International Volume 2020, Article ID 2509039, 6 pages
es_ES
Identifier
dc.identifier.other
10.1155/2020/2509039
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178389
Abstract
dc.description.abstract
In-stent restenosis (ISR) is one of the main complications in patients undergoing percutaneous coronary angioplasty, and microRNAs participate in the contractile-to-synthetic phenotypic switch of vascular smooth muscle cells, a hallmark of restenosis development. MicroRNAs (miRNAs) can be released into circulation from injured tissues, enticing a potential role as noninvasive biomarkers. We aimed to evaluate circulating levels of miRNA-23b, miRNA-143, and miRNA-145 as diagnostic markers of ISR. 142 patients with coronary artery disease undergoing successful angioplasty and a follow-up angiography were included. Subjects were classified according to the degree of obstruction at the angioplasty site into cases (>= 50%) or controls (<50%). Total RNA was isolated from plasma to quantify circulating miRNAs levels, and the ROC curves were constructed. Among circulating miRNAs assessed, miRNA-23b and miRNA-143 were significantly lower in cases (miRNA-23b:18.4x10-5and miRNA-143:13.7x10-5) than controls (miRNA-23b:5.2x10-5,p<0.0001; miRNA-143:4.0x10-5,p<0.0001). Plasma levels of miRNA-145 showed no significant differences. The analysis of the ROC curves showed an area under the curve for miRNA-23b of 0.71 (95% CI: 0.62-0.80,p<0.0001) and 0.69 for miRNA-143 (95% CI: 0.60-0.78;p<0.0001). Our data suggest that plasma levels of miRNA-23b and miRNA-143 could be useful as noninvasive biomarkers of ISR.
es_ES
Patrocinador
dc.description.sponsorship
Comisión Nacional de Investigación Científica y Tecnológica (CONICYT)
CONICYT FONDECYT
1171765
1141292
3170785
Dirección de Investigación of the Universidad de La Frontera
DI15-0033
DI19-2018